Ana Sayfa | Dergi Hakkında | Yayın Kurulu | Bilimsel Danışma Kurulu | İçindekiler | Arşiv | Yayın Arama | Yazarlara Bilgi | İletişim  
2019, Cilt 33, Sayı 3, Sayfa(lar) 169-175   
THE ROLE OF EOSINOPHILS AT MILD AND MODERATE COPD EXACERBATIONS
Deniz DOĞAN, Yakup ARSLAN
Sağlık Bilimleri Üniversitesi Gülhane Eğitim Araştırma Hastanesi, Göğüs Hastalıkları Anabilimdalı, Ankara, Türkiye
Keywords: COPD, COPD exacerbation, eosinophil

Aim: To determine the relationship between serum eosinophil values with exacerbation severity in patients with mild and moderate Chronic Obstructive Pulmonary Disease Exacerbation.

Material and Methods: Data of 254 patients diagnosed as COPD who applied to the Chest Diseases Polyclinic between January 1st with December 31th of 2017 were retrospectively reviewed. Patients were divided into two groups according to their clinical and laboratory findings; patients treated and followed up with outpatient treatment named as “mildly exacerbated-group 1”, and patients treated and followed up as hospitalized named as “ moderately exacerbated-group 2”. The demographic characteristics of the patients and their biochemical values, especially eosinophil value, were compared between the two groups.

Results: Serum eosinophils (2.4±1.7 vs 1.1±1.3, p <0.001) and lymphocytes (23.7±39.2 versus 14.7±8.5, p <0.001) were significantly higher in patients with mild exacerbation. In contrast, neutrophil rates were higher in patients diagnosed with moderate exacerbation (75.5±10.6% versus 64.5±10.2%, p <0.001). Similarly, hS-CRP (62.1±56.9 versus 18.7±11.6, p <0.001) and neutrophil / lymphocyte ratio (9.1±12.8 versus 3.5±2.6, p <0.001) were significantly higher in patients with moderate exacerbation. In our study, when the upper limit for serum eosinophilia was 2%, it was found that the rate of patients with less than 2% in patients with moderate exacerbation was significantly higher (78.8 % versus 46.3 %, p <0.001).

Conclusion: In COPD exacerbations, serum eosinophil value may be variable, clinical and laboratory findings should be evaluated together to determine the optimal treatment modality in these patients.